Page last updated: 2024-09-04

atazanavir sulfate and pyrimidinones

atazanavir sulfate has been researched along with pyrimidinones in 99 studies

Compound Research Comparison

Studies (atazanavir sulfate)	Trials (atazanavir sulfate)	Recent Studies (post-2010) (atazanavir sulfate)	Studies (pyrimidinones)	Trials (pyrimidinones)	Recent Studies (post-2010) (pyrimidinones)
1,102	246	590	6,059	604	2,692

Research

Studies (99)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	76 (76.77)	29.6817
2010's	23 (23.23)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bartlett, JG	1
Korn, K; Moschik, G; Paatz, C; Schmidt, B; Schnell, T; Thein, C; Walter, H	1
Moyle, GJ	1
Sax, PE	1
Wehr, A	1
DeGoey, DA; Randolph, JT	1
Currie, A; Fiedorek, FT; Grasela, DM; Haas, DW; Hodder, SL; Noor, MA; O'Mara, E; Parker, RA	1
Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; Rightmire, A; Rodriguez, C; Sankoh, S; Wilber, R	2
Jaillon, P; Poirier, JM; Robidou, P	1
Adler, E; Cohen, C; Fessel, WJ; Gladysz, A; Gonzalez-Garcia, J; McGovern, R; McLaren, C; Nieto-Cisneros, L; Zala, C	1
Hill, A	1
Hruz, PW; Yan, Q	1
Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; McLaren, C; Odeshoo, L; Rightmire, A; Rodriguez, C; Wirtz, V	1
Biollaz, J; Buclin, T; Cavassini, M; Colombo, S; Decosterd, LA; Franc, C; Guignard, N; Khonkarly, M; Rochat, B; Tarr, PE; Telenti, A	1
Crane, HM; Kitahata, MM; Van Rompaey, SE	1
Azuaje, C; Crespo, M; Curran, A; Diaz, M; Feijoo, M; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E	1
Flint, OP; Maa, JF; Noor, MA; Parker, RA	1
Johnson, M	1
de Hoon, J; Van Wijngaerden, E; Verbesselt, R	1
Aouadi, M; Binétruy, B; Cardot-Leccia, N; Dellamonica, P; Durant, J; Garraffo, R; Heripret, L; Lavrut, T; Le Marchand-Brustel, Y; Perrin, C; Prot, M	1
Balfour, HH; Brundage, RC; Vezina, HE; Weller, DR	1
Baker, RK; Brooks, JT; Buchacz, K; Chmiel, JS; Moorman, A; Wood, KC; Young, B	1
Chan-Tack, KM; Fantry, LE; Gilliam, BL; Qaqish, RB; Redfield, RR; Rode, RA	1
Brun, S; Chumney, EC; King, MS; Luo, MP; Simpson, KN	1
Choi, SO; Kashuba, AD; Rezk, NL	1
DiFrancesco, R; Fischl, MA; Gripshover, B; Hochreitter, J; Keil, K; Morse, GD; Reichman, RC; Zingman, BS	1
Brazeau, D; DiFrancesco, R; Fischl, MA; Forrest, A; Gripshover, BM; Ma, Q; Morse, GD; Reichman, RC; Slish, JC; Venuto, CS; Zingman, BS	1
Barreiro, P; Gonzalez-Lahoz, J; Jiménez-Nácher, I; Labarga, P; Martín-Carbonero, L; Rodríguez-Novoa, S; Ruiz, A; Soriano, V	1
Agarwala, S; Barditch-Crovo, P; Carson, K; Flexner, C; Fuchs, E; Parsons, T; Pham, PA; Vasist, L	1
Clavel, F; Dam, E; Essioux, L; Faudon, JL; Hill, A; Lebel-Binay, S; Rochas, S; Schutz, M; Thibaut, L; Thomas, CM	1
Bernal, E; Gutiérrez, F; Martín-Hidalgo, A; Masiá, M; Padilla, S; Ramos, JM	1
Back, D; Boffito, M; Bonora, S; D'Avolio, A; Else, L; Gazzard, B; Mandalia, S; Moyle, G; Nelson, M; Pozniak, A; Waters, LJ	1
Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF	1
Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R	1
Boston, NS; Brazeau, D; Catanzaro, L; DiFrancesco, R; Fischl, MA; Forrest, A; Gripshover, B; Ma, Q; Morse, GD; Reichman, RC; Slish, J; Zingman, BS	1
Arribas, JR; Pulido, F	1
Barreiro, P; Blanco, F; de Mendoza, C; García-Gasco, P; González-Lahoz, J; Martín-Carbonero, L; Morello, J; Rivas, P; Rodríguez-Novoa, S; Ruiz-Sancho, A; Soriano, V; Vispo, E	1
Dietz, B; Jones, WJ; Rajagopalan, R; Simpson, KN	1
Castagna, A; Caumo, A; Galli, L; Guffanti, M; Lazzarin, A; Luzi, L; Perseghin, G	1
Hruz, PW; Jay, PY; Struthers, H; Yan, Q	1
Bacarelli, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Navarra, P; Ragazzoni, E; Regazzi, M; Villani, P	1
Babacan, E; Kaykhin, P; Lötsch, J; Staszewski, S; Stephan, C; Stürmer, M; von Hentig, N	1
Beck, K; Cai, Y; Causemaker, SJ; Chiu, YL; Doan, T; Esslinger, HU; Hanna, GJ; King, KR; Klein, CE; Podsadecki, TJ	1
Chen, L; Chen, X; He, Z; Peng, N; Qin, L; You, J	1
Bertilsson, L; Böttiger, Y; Diczfalusy, U; Flamholc, L; Gisslén, M; Josephson, F; Ormaasen, V; Sönnerborg, A	1
Dubé, MP; Greenwald, M; Mather, KJ; Shen, C	1
Fu, W; Hu, WS; Moore, MD; Nagashima, K; Pathak, VK; Ptak, RG; Soheilian, F	1
Keiser, PH; Nassar, N	1
Frank, I; Torti, C	1
Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Thiry, A; Yang, R	1
Chin, BS; Choi, H; Choi, JY; Choi, SH; Han, SH; Jeong, SJ; Kim, CO; Kim, JM; Kim, MS; Lee, HS; Song, YG	1
Batterham, M; Chan, DJ; McNally, L; Ray, JE; Smith, DE	1
Louis, JM; Sayer, JM	1
Boesmans, D; Di Fazio, V; Elens, L; Haufroid, V; Vanbinst, R; Veriter, S; Wallemacq, P	1
Back, D; Boffito, M; Else, L; Gazzard, B; Khoo, S; Moyle, G; Pozniak, A; Sousa, M; Taylor, J	1
Bierman, WF; Boucher, CA; Danner, SA; Nijhuis, M; van Agtmael, MA	1
Ameli, N; Anastos, K; Bacchetti, P; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Huang, Y; Hyman, CL; Levine, A; Young, M	1
Dietz, B; Rajagopalan, R; Simpson, KN	1
Moreno, V; Valencia, ME	1
Aranda, M; Arranz, JA; Blanco, JL; Clotet, B; Cosin, J; Cruceta, A; Dalmau, D; Domingo, P; Ferrer, E; García, I; Gatell, JM; Gutiérrez, F; Knobel, H; Lazzari, Ed; Llibre, JM; Mallolas, J; Martínez, E; Milinkovic, A; Murillas, J; Pedrol, E; Pich, J; Podzamczer, D; Ribera, E; Roca, V; Vidal, F	1
Chen, CY; Grinspoon, SK; Hadigan, CM; Joy, T; Liebau, JG; Makimura, H; Robbins, GK; Stanley, TL; Thomas, BJ; Weise, SB	1
Chetchotisakd, P	1
Chang, SC; Chang, SY; Chen, MY; Hsieh, SM; Hung, CC; Sheng, WH	1
Sankawa, Y	1
Ainsworth, J; Anderson, J; Back, D; Bansi, L; Dunn, D; Easterbrook, P; Fisher, M; Gazzard, B; Gibbons, S; Gilson, R; Hill, T; Johnson, M; Khoo, S; Leen, C; Orkin, C; Pillay, D; Sabin, C; Stöhr, W; Winston, A	1
Anceschi, MM; Ascenzi, P; Ivanovic, J; Mattia, E; Narciso, P; Nicastri, E; Notari, S; Pisani, G; Pucillo, LP; Signore, F; Tempestilli, M; Vallone, C	1
Andersson, MC; Böttiger, Y; Flamholc, L; Gisslén, M; Hagberg, L; Josephson, F; Ormaasen, V; Sönnerborg, A; Vesterbacka, J	1
Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R	1
Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R	1
Carper, MJ; Lei, X; Ramanadham, S; Richmond, SR; Yarasheski, KE; Zhang, S	1
Hylemon, PB; Li, X; Liang, G; Pandak, WM; Studer, EJ; Wang, G; Xiao, J; Zha, W; Zhou, H	1
Babiker, A; Fox, L; Gey, D; Lopardo, G; Markowitz, N; Paton, N; Tavel, JA; Wentworth, D; Wyman, N	1
Burger, DM; Faraj, D; Gelinck, L; Kroon, F; Kuks, PF; Richter, C; Van der Ende, ME; Van der Ven, A; van Luin, M; Van Schaik, RH; Visser, M; Wit, FW	1
Lisovsky, I; Martinez-Cajas, JL; Moisi, D; Oliveira, M; Schader, SM; Wainberg, MA	1
Andersson, LM; Andersson, O; Edén, A; Flamholc, L; Gisslén, M; Josephson, F; Nilsson, S; Ormaasen, V; Säll, C; Sönnerborg, A; Svedhem, V; Tunbäck, P	1
Absalon, J; Malan, N; Mancini, M; McGrath, D; Su, J; Wirtz, V; Yang, R	1
Auclair, M; Bastard, JP; Boccara, F; Capeau, J; Caron-Debarle, M; Cohen, A; Lefèvre, C; Prot, M	1
Bierman, WF; Danner, SA; Jansen, G; Scheffer, GL; Scheper, RJ; Schoonderwoerd, A; van Agtmael, MA	1
Fessel, WJ; Hellinger, J; Kaufman, D; Rhee, SY; Ruane, P; Shafer, RW; Shirvani, V; Taylor, J; Towner, W; Troia, P; Zolopa, A	1
Antoine, B; Capeau, J; Chapron, C; Kadiri, S; Leroyer, S; Quette, J; Vatier, C	1
Absalon, J; Johnson, M; McGrath, D; Sheppard, L; Squires, KE; Uy, J; Yang, R	1
de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C	1
Alaeus, A; Heeg, B; Lescrauwaet, B; Neubauer, A; Sennfält, K; Thuresson, PO	1
Callebaut, C; Cihlar, T; Hruz, PW; Koster, J; Tsai, L; Xu, L; Yan, Q	1
Bentley, TG; Broder, MS; Chang, EY; Juday, T; Uy, J	1
Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N	1
Anu, R; Cauda, R; De Donatis, GM; Gillet, JP; Gottesman, MM; Handley, M; Lucia, MB; Wu, CP	1
Amole, CD; Brisebois, C; Brown Ripin, DH; Essajee, S; Koehler, E; Levin, AD; Moore, MC; Sickler, JJ; Singh, IR	1

Reviews

5 review(s) available for atazanavir sulfate and pyrimidinones

Article	Year
Boosted PIs: competition hots up. The AIDS reader, 2003, Volume: 13, Issue:9 Topics: Atazanavir Sulfate; Drug Administration Schedule; HIV Infections; Humans; Indinavir; Lopinavir; Oligopeptides; Protease Inhibitors; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Saquinavir	2003
Peptidomimetic inhibitors of HIV protease. Current topics in medicinal chemistry, 2004, Volume: 4, Issue:10 Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane	2004
Quality control of protease inhibitors. Journal of pharmaceutical sciences, 2008, Volume: 97, Issue:6 Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides	2008
HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS (London, England), 2009, Jan-28, Volume: 23, Issue:3 Topics: Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load	2009
The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients. Expert review of anti-infective therapy, 2009, Volume: 7, Issue:7 Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Treatment Outcome	2009

Trials

29 trial(s) available for atazanavir sulfate and pyrimidinones

Article	Year
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients. AIDS clinical care, 2003, Volume: 15, Issue:9 Topics: Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load	2003
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS (London, England), 2004, Nov-05, Volume: 18, Issue:16 Topics: Adult; Analysis of Variance; Atazanavir Sulfate; Cross-Over Studies; Double-Blind Method; Energy Metabolism; Fatty Acids, Nonesterified; Glycogen; HIV Protease Inhibitors; HIV Seronegativity; Humans; Insulin Resistance; Lipids; Lipodystrophy; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones	2004
Boosted Reyataz comparable to Kaletra. AIDS patient care and STDs, 2005, Volume: 19, Issue:1 Topics: Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Male; Maximum Tolerated Dose; Oligopeptides; Probability; Pyridines; Pyrimidinones; Risk Assessment; Severity of Illness Index; Treatment Outcome	2005
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS (London, England), 2005, Apr-29, Volume: 19, Issue:7 Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Drug Administration Schedule; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Viral Load	2005
Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Current medical research and opinion, 2005, Volume: 21, Issue:10 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Cholesterol, LDL; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Protease Inhibitors; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Triglycerides	2005
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS (London, England), 2006, Mar-21, Volume: 20, Issue:5 Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Time Factors; Treatment Outcome	2006
Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Antiviral therapy, 2006, Volume: 11, Issue:1 Topics: Adult; Atazanavir Sulfate; Blood Proteins; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Protein Binding; Pyridines; Pyrimidinones; Ritonavir; Treatment Outcome	2006
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS (London, England), 2006, Sep-11, Volume: 20, Issue:14 Topics: Adipocytes; Adult; Atazanavir Sulfate; Cell Differentiation; Cross-Over Studies; Drug Combinations; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; HIV Protease Inhibitors; HIV Seronegativity; Humans; Insulin Resistance; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir	2006
Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort. Journal of acquired immune deficiency syndromes (1999), 2006, Dec-15, Volume: 43, Issue:5 Topics: Adenine; Adult; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; Humans; Kidney; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; Tenofovir	2006
Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir. Journal of acquired immune deficiency syndromes (1999), 2007, Jun-01, Volume: 45, Issue:2 Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Therapy, Combination; Female; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir	2007
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antiviral therapy, 2007, Volume: 12, Issue:5 Topics: Adult; Area Under Curve; Atazanavir Sulfate; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir	2007
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:1 Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Blood Glucose; CD4 Lymphocyte Count; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Pyrimidinones; RNA, Viral; Treatment Outcome	2008
CASTLE study showed similar efficacy. AIDS patient care and STDs, 2008, Volume: 22, Issue:3 Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load	2008
Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir. Journal of clinical pharmacology, 2008, Volume: 48, Issue:5 Topics: Adult; Anti-HIV Agents; Anti-Ulcer Agents; Area Under Curve; Atazanavir Sulfate; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Female; Histamine H2 Antagonists; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Omeprazole; Pyridines; Pyrimidinones; Ranitidine; Ritonavir	2008
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. European journal of clinical pharmacology, 2008, Volume: 64, Issue:8 Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Enzyme Induction; Enzyme Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxycholesterols; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Young Adult	2008
No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Aug-15, Volume: 47, Issue:4 Topics: Adult; Atazanavir Sulfate; Drug Therapy, Combination; Endothelium, Vascular; Glucose; Glucose Clamp Technique; HIV Protease Inhibitors; HIV Seronegativity; Humans; Insulin Resistance; Lopinavir; Male; Muscle, Skeletal; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Treatment Outcome; Vasodilation	2008
Anti-HIV agents. The Castle study: lopinavir vs. atazanavir. TreatmentUpdate, 2008, Volume: 20, Issue:2 Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Pyrimidinones; Viral Load	2008
A king in the CASTLE? Optimum initial HIV protease inhibitor. Lancet (London, England), 2008, Aug-23, Volume: 372, Issue:9639 Topics: Atazanavir Sulfate; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Tablets; Viral Load	2008
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet (London, England), 2008, Aug-23, Volume: 372, Issue:9639 Topics: Adult; Aged; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load	2008
CASTLE data show no gender differences. AIDS patient care and STDs, 2008, Volume: 22, Issue:9 Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Pyrimidinones; Sex Factors; Viral Load	2008
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antiviral therapy, 2008, Volume: 13, Issue:7 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Treatment Outcome	2008
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. Journal of acquired immune deficiency syndromes (1999), 2009, May-01, Volume: 51, Issue:1 Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; Atazanavir Sulfate; Drug Resistance, Viral; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Lipids; Liver; Lopinavir; Male; Middle Aged; Mutation; Oligopeptides; Pyridines; Pyrimidinones; Safety	2009
Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients. AIDS (London, England), 2009, Jul-17, Volume: 23, Issue:11 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; Glucose; HIV Infections; HIV Protease Inhibitors; Humans; Intra-Abdominal Fat; Lipid Metabolism; Lopinavir; Male; Middle Aged; Muscle, Skeletal; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir	2009
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 53, Issue:3 Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult	2010
Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. PloS one, 2010, Feb-23, Volume: 5, Issue:2 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Furans; HIV Infections; Humans; Interleukin-2; Lopinavir; Male; Nausea; Oligopeptides; Opportunistic Infections; Organophosphates; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Treatment Outcome	2010
Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients. AIDS research and human retroviruses, 2010, Volume: 26, Issue:5 Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome	2010
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. AIDS care, 2010, Volume: 22, Issue:6 Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Irritable Bowel Syndrome; Lopinavir; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Pyrimidinones; Quality of Life; Ritonavir; Surveys and Questionnaires; Tenofovir; Young Adult	2010
Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:2 Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Sex Factors	2011
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. Antiviral therapy, 2010, Volume: 15, Issue:8 Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load	2010

Other Studies

65 other study(ies) available for atazanavir sulfate and pyrimidinones

Article	Year
Report on new drugs. The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 2000, Volume: 12, Issue:2 Topics: Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Dioxolanes; Drugs, Investigational; Humans; Imidazoles; Lopinavir; Oligopeptides; Purine Nucleosides; Pyridines; Pyrimidinones; Pyrones; Sulfonamides; Sulfur Compounds	2000
Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples. AIDS (London, England), 2003, May-23, Volume: 17, Issue:8 Topics: Atazanavir Sulfate; Carbamates; Drug Resistance, Multiple, Viral; Furans; HIV; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Sulfonamides	2003
[Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r]. MMW Fortschritte der Medizin, 2003, Dec-11, Volume: 145, Issue:50 Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Organophosphates; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Time Factors; Viral Load	2003
[New treatment options for HIV-infected patients]. Deutsche medizinische Wochenschrift (1946), 2004, May-07, Volume: 129, Issue:19 Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Time Factors	2004
[Simplified HIV therapy. Atazanavir: the first protease inhibitor with once daily administration]. MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1 Topics: Adult; Atazanavir Sulfate; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome	2004
[Atazanavir protects lipid metabolism. New PI with favorable metabolic profile]. MMW Fortschritte der Medizin, 2004, Apr-26, Volume: 146 Spec No 1 Topics: Atazanavir Sulfate; Blood Glucose; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load	2004
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS (London, England), 2005, Jan-28, Volume: 19, Issue:2 Topics: Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir	2005
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi Therapeutic drug monitoring, 2005, Volume: 27, Issue:2 Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides	2005
Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles? AIDS (London, England), 2005, Nov-18, Volume: 19, Issue:17 Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome	2005
Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. Journal of acquired immune deficiency syndromes (1999), 2005, Dec-01, Volume: 40, Issue:4 Topics: Adipocytes; Animals; Atazanavir Sulfate; Carbamates; Deoxyglucose; Dose-Response Relationship, Drug; Furans; Glucose; Glucose Clamp Technique; HIV Protease Inhibitors; Infusions, Intravenous; Insulin Resistance; Lopinavir; Male; Models, Animal; Muscle, Skeletal; Myocardium; Oligopeptides; Pyridines; Pyrimidinones; Rats; Ritonavir; Sulfonamides	2005
[New data on atazanavir/r]]. MMW Fortschritte der Medizin, 2005, Apr-25, Volume: 147 Spec No 1 Topics: Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome; Viral Load	2005
Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS (London, England), 2006, Apr-24, Volume: 20, Issue:7 Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Blood Pressure; Body Mass Index; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Protease Inhibitors; Humans; Hypertension; Indinavir; Longitudinal Studies; Lopinavir; Male; Middle Aged; Nelfinavir; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir	2006
Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS (London, England), 2006, May-12, Volume: 20, Issue:8 Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Combinations; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir; Salvage Therapy; Treatment Failure; Treatment Outcome; Viral Load	2006
Response to "Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?" by Hill. AIDS (London, England), 2006, Oct-03, Volume: 20, Issue:15 Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Patient Selection; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome	2006
Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Jan-01, Volume: 845, Issue:1 Topics: Atazanavir Sulfate; Calibration; Carbamates; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Fluorescence; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides; Ultraviolet Rays	2007
Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:12 Topics: Adipose Tissue; Animals; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Interactions; HIV Protease Inhibitors; Hypertriglyceridemia; Lopinavir; Male; Mice; Mice, Inbred C57BL; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Messenger; Time Factors; Triglycerides	2006
An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Apr-01, Volume: 848, Issue:2 Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet; Sulfonamides	2007
Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients. AIDS patient care and STDs, 2006, Volume: 20, Issue:11 Topics: Adult; Aged; Atazanavir Sulfate; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir	2006
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease. Clinical drug investigation, 2007, Volume: 27, Issue:1 Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Fees, Pharmaceutical; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Models, Statistical; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Survival Analysis; Survival Rate; Time Factors	2007
High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. Journal of pharmaceutical and biomedical analysis, 2007, Mar-12, Volume: 43, Issue:4 Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Structure; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Time Factors	2007
Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application. Therapeutic drug monitoring, 2007, Volume: 29, Issue:1 Topics: Atazanavir Sulfate; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Quality Control; Reference Standards; Reproducibility of Results; Ritonavir; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Time Factors	2007
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics, 2007, Volume: 8, Issue:3 Topics: Adult; Aged; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Female; Gene Frequency; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Pyridines; Pyrimidinones	2007
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. The Journal of infectious diseases, 2007, Apr-01, Volume: 195, Issue:7 Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Lopinavir; Male; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Ritonavir; Severity of Illness Index	2007
Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir. Antiviral therapy, 2007, Volume: 12, Issue:3 Topics: Atazanavir Sulfate; Cell Line, Tumor; Drug Resistance, Viral; Drug Synergism; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Lopinavir; Microbial Sensitivity Tests; Oligopeptides; Pyridines; Pyrimidinones; Recombination, Genetic; Saquinavir; Transfection	2007
[Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir]. Medicina clinica, 2007, Jul-14, Volume: 129, Issue:7 Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Time Factors	2007
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (London, England), 2007, Sep-12, Volume: 21, Issue:14 Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine	2007
Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Therapeutic drug monitoring, 2007, Volume: 29, Issue:5 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Substance-Related Disorders; United States	2007
Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy. Journal of acquired immune deficiency syndromes (1999), 2007, Sep-01, Volume: 46, Issue:1 Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lopinavir; Oligopeptides; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir	2007
Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain. Clinical drug investigation, 2007, Volume: 27, Issue:12 Topics: Adult; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; France; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Lopinavir; Male; Markov Chains; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Risk Factors; Ritonavir; Spain; Time Factors; United Kingdom	2007
Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity. AIDS (London, England), 2007, Nov-12, Volume: 21, Issue:17 Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Combinations; Glucose Clamp Technique; Humans; Insulin; Insulin Resistance; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir	2007
HIV protease inhibitors that block GLUT4 precipitate acute, decompensated heart failure in a mouse model of dilated cardiomyopathy. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2008, Volume: 22, Issue:7 Topics: Animals; Atazanavir Sulfate; Blood Glucose; Cardiomyopathy, Dilated; Deoxyglucose; Disease Models, Animal; Echocardiography; Glucose Tolerance Test; Glucose Transporter Type 4; Heart Failure; HIV Protease Inhibitors; Humans; Insulin Resistance; Lopinavir; Mice; Myocardium; Oligopeptides; Pulmonary Edema; Pyridines; Pyrimidinones	2008
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. HIV medicine, 2008, Volume: 9, Issue:4 Topics: Adult; Aged; Atazanavir Sulfate; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pilot Projects; Prospective Studies; Pyridines; Pyrimidinones; Ritonavir	2008
Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:6 Topics: Atazanavir Sulfate; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Salvage Therapy; Treatment Outcome	2008
Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:7 Topics: Animals; Antimalarials; Atazanavir Sulfate; Chloroquine; Drug Resistance; Drug Synergism; Female; HIV Protease Inhibitors; Humans; In Vitro Techniques; Lopinavir; Malaria; Mice; Nelfinavir; Oligopeptides; Plasmodium chabaudi; Plasmodium falciparum; Pyridines; Pyrimidinones; Ritonavir; Saquinavir	2008
Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation. Virology, 2008, Sep-15, Volume: 379, Issue:1 Topics: Atazanavir Sulfate; Dimerization; gag Gene Products, Human Immunodeficiency Virus; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microscopy, Electron, Transmission; Oligopeptides; Pyridines; Pyrimidinones; RNA, Viral; Virion	2008
Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study. International journal of STD & AIDS, 2008, Volume: 19, Issue:8 Topics: Anti-HIV Agents; Atazanavir Sulfate; Databases, Factual; Drug Interactions; Drug Therapy, Combination; Female; Histamine H2 Antagonists; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medical Audit; Multivariate Analysis; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Time Factors; Treatment Failure; Treatment Outcome; Viral Load	2008
Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy. Journal of Korean medical science, 2008, Volume: 23, Issue:4 Topics: Adult; Atazanavir Sulfate; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir	2008
Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs. Current HIV research, 2008, Volume: 6, Issue:5 Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Blood; Chromatography, High Pressure Liquid; Cohort Studies; Cross-Sectional Studies; HIV Infections; HIV-1; Humans; Longitudinal Studies; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Plasma; Pyridines; Pyrimidinones; RNA, Viral; Semen; Statistics as Topic; Viral Load	2008
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin. Proteins, 2009, May-15, Volume: 75, Issue:3 Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides	2009
Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. Clinical chemistry, 2009, Volume: 55, Issue:1 Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Solid Phase Extraction; Sulfonamides	2009
96-week CASTLE data show similar efficacy results. AIDS patient care and STDs, 2008, Volume: 22, Issue:11 Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load	2008
Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS (London, England), 2009, Feb-20, Volume: 23, Issue:4 Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Monitoring; Epidemiologic Methods; Female; Hair; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Middle Aged; Oligopeptides; Patient Compliance; Pyridines; Pyrimidinones; Ritonavir; Specimen Handling; Treatment Outcome; Viral Load	2009
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Advances in therapy, 2009, Volume: 26, Issue:2 Topics: Anti-HIV Agents; Atazanavir Sulfate; Budgets; CD4 Lymphocyte Count; Coronary Disease; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Therapy, Combination; HIV Infections; Humans; Life Expectancy; Lopinavir; Markov Chains; Models, Econometric; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Smoking; United States	2009
[Atazanavir-induced nephrolithiasis]. Enfermedades infecciosas y microbiologia clinica, 2009, Volume: 27, Issue:2 Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir	2009
Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes. Prescrire international, 2009, Volume: 18, Issue:101 Topics: Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Drug Approval; Drug Therapy, Combination; Europe; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Jaundice; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Torsades de Pointes; Viral Load	2009
Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure. BMC infectious diseases, 2009, Sep-14, Volume: 9 Topics: Adult; Atazanavir Sulfate; DNA Mutational Analysis; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Young Adult	2009
[Medication change due to side effects or possible long-term complications. Side effect management with vision]. MMW Fortschritte der Medizin, 2009, Apr-30, Volume: 151, Issue:18 Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Long-Term Care; Lopinavir; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic	2009
Factors influencing lopinavir and atazanavir plasma concentration. The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:1 Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Weight; Cyclopropanes; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; Pyrimidinones; Rifabutin; United Kingdom	2010
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women. Current HIV research, 2009, Volume: 7, Issue:6 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Atazanavir Sulfate; Birth Weight; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Lopinavir; Maternal-Fetal Exchange; Nelfinavir; Nevirapine; Oligopeptides; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyridines; Pyrimidinones	2009
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients. European journal of clinical pharmacology, 2010, Volume: 66, Issue:4 Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Bilirubin; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; HIV-1; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome; Viral Load	2010
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Archives of internal medicine, 2010, Jan-11, Volume: 170, Issue:1 Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine	2010
HIV-protease inhibitors suppress skeletal muscle fatty acid oxidation by reducing CD36 and CPT1 fatty acid transporters. Biochimica et biophysica acta, 2010, Volume: 1801, Issue:5 Topics: Animals; Atazanavir Sulfate; Carnitine O-Palmitoyltransferase; CD36 Antigens; Cell Line; Darunavir; Dose-Response Relationship, Drug; Fatty Acid Transport Proteins; Fatty Acids; HIV Protease Inhibitors; Humans; Lopinavir; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; Oligopeptides; Oxidation-Reduction; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides	2010
Berberine inhibits HIV protease inhibitor-induced inflammatory response by modulating ER stress signaling pathways in murine macrophages. PloS one, 2010, Feb-09, Volume: 5, Issue:2 Topics: Animals; Antigens, Surface; Atazanavir Sulfate; Berberine; Blotting, Western; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; ELAV Proteins; ELAV-Like Protein 1; Endoplasmic Reticulum; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; HIV Protease Inhibitors; Inflammation Mediators; Interleukin-6; Lopinavir; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA-Binding Proteins; Signal Transduction; Tumor Necrosis Factor-alpha	2010
Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. AIDS (London, England), 2010, May-15, Volume: 24, Issue:8 Topics: Adolescent; Adult; Aged; Alkynes; Atazanavir Sulfate; Atovaquone; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Proguanil; Pyridines; Pyrimidinones; Ritonavir; Young Adult	2010
HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:7 Topics: Anti-HIV Agents; Atazanavir Sulfate; Cell Line; Cells, Cultured; Codon; Genotype; HIV Infections; HIV Protease; HIV-1; Humans; Lopinavir; Nelfinavir; Oligopeptides; Polymorphism, Genetic; Pyridines; Pyrimidinones	2010
HIV protease inhibitors activate the adipocyte renin angiotensin system. Antiviral therapy, 2010, Volume: 15, Issue:3 Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atazanavir Sulfate; Benzimidazoles; Benzoates; Biphenyl Compounds; HIV Protease Inhibitors; Humans; Irbesartan; Lopinavir; Mice; Oligopeptides; PPAR gamma; Pyridines; Pyrimidinones; Renin-Angiotensin System; Ritonavir; Telmisartan; Tetrazoles	2010
Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:8 Topics: Atazanavir Sulfate; ATP-Binding Cassette Transporters; Cell Line; Drug Resistance, Multiple; Enzyme Inhibitors; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir	2010
HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10 Topics: Atazanavir Sulfate; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Least-Squares Analysis; Lopinavir; Mutation; Nelfinavir; Oligopeptides; Organophosphates; Polymorphism, Genetic; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides	2010
Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue. Journal of lipid research, 2011, Volume: 52, Issue:2 Topics: Adult; Atazanavir Sulfate; Carrier Proteins; Female; Gene Expression; HIV Protease Inhibitors; Humans; Inflammation; Interleukin-6; Intra-Abdominal Fat; Lopinavir; Male; Nelfinavir; Oligopeptides; Perilipin-1; Phosphoenolpyruvate Carboxykinase (GTP); Phosphoproteins; Pyridines; Pyrimidinones; Ritonavir; Sesquiterpenes; Subcutaneous Fat; Triglycerides; Tumor Necrosis Factor-alpha	2011
Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden. Scandinavian journal of infectious diseases, 2011, Volume: 43, Issue:4 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Cost-Benefit Analysis; HIV Infections; HIV-1; Humans; Lopinavir; Models, Statistical; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Sweden	2011
GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:4 Topics: Adipocytes; Animals; Atazanavir Sulfate; Biological Transport; Cells, Cultured; Glucose; Glucose Clamp Technique; HIV Protease Inhibitors; Homeostasis; Humans; Insulin; Lopinavir; Male; Mice; Molecular Structure; Oligopeptides; Pyridines; Pyrimidinones; Rats; Rats, Wistar; Ritonavir	2011
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States. Journal of medical economics, 2011, Volume: 14, Issue:2 Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Markov Chains; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Tenofovir; United States	2011
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS (London, England), 2011, Aug-24, Volume: 25, Issue:13 Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides	2011
Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells. British journal of cancer, 2011, Aug-09, Volume: 105, Issue:4 Topics: Antibiotics, Antineoplastic; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Sarcoma, Kaposi; Treatment Outcome	2011
Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries. Journal of acquired immune deficiency syndromes (1999), 2011, Volume: 57 Suppl 2 Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Developing Countries; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Health Planning; Health Services; HIV Infections; Humans; Lamivudine; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome	2011